ArticleRheumatology and therapy2023

Safety and Effectiveness of Baricitinib in Chinese Patients with Moderate-to-Severe Rheumatoid Arthritis: 24-Week Results from a Post-Marketing Safety Study.

Chan-Yuan Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.